Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of inhaled seralutinib in pulmonary arterial hypertension
2023-506334-75-00Phase 3Authorised
- Sponsor
- GB002, Inc.
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 31
01
Overview
Phase 3, open-label, single-arm trial of seralutinib in pulmonary arterial hypertension (PAH), sponsored by GB002, Inc. Primary endpoint: Incidence of treatment-emergent adverse events (TEAEs). Planned start Jul 2024; status: authorised.
02
Drugs
seralutinib
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2023-506334-75-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506334-75-00.